))
Parents on a Mission
Manage episode 312495042 series 3236617
İçerik David Cunnington and SCN2A Australia tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan David Cunnington and SCN2A Australia veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
Having a child with SCN2A or other genetic epilepsy is challenging and the future is uncertain. When Alex Nemiroff’s son Roger was born, he was determined to work towards finding treatments for SCN2A. Alex is now the CEO of RogCon, which has a research program (RC-222) developing an antisense oligonucleotide (ASO) treatment for gain-of-function epilepsies.
Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.
Leave a review and subscribe via Apple Podcasts.
You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app
Links:
- RogCon
- Antisense oligonucleotide therapy for SCN2A gain-of-function epilepsies – poster presented at AES 2018
See omnystudio.com/listener for privacy information.
28 bölüm
Paylaş
